Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...
Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...
During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...
Vertex Pharmaceuticals (VRTX) reported $3.08 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 11%. EPS of $4.80 for the same period compares to $4.38 ...
Advocacy groups form a buyer’s club to obtain generic versions of pricey Vertex cystic fibrosis drug
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
A new COPILOT function in Excel lets you use AI in a formula. The new skill is now available to Microsoft 365 insiders. Reduces some of the complexity involved in creating formulas. Get more in-depth ...
Vertex Pharmaceuticals (NASDAQ:VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet the primary endpoint in the Phase 2 pain study, offsetting a strong quarterly ...
Ms. O’Rourke is the executive editor of The Yale Review and a professor of creative writing at Yale University. July 18, 2025 When I first told ChatGPT who I was, it sent a gushing reply: “Oh wow — it ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2025 financial results on Monday, August 4, 2025 after the financial markets close. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback